Aptorum Group (APM) Competitors $1.45 +0.02 (+1.40%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APM vs. LPCN, ITRM, ESLA, ENLV, NAII, INKT, ICCC, PLUR, BTAI, and EYENShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Lipocine (LPCN), Iterum Therapeutics (ITRM), Estrella Immunopharma (ESLA), Enlivex Therapeutics (ENLV), Natural Alternatives International (NAII), MiNK Therapeutics (INKT), ImmuCell (ICCC), Pluri (PLUR), BioXcel Therapeutics (BTAI), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Lipocine Iterum Therapeutics Estrella Immunopharma Enlivex Therapeutics Natural Alternatives International MiNK Therapeutics ImmuCell Pluri BioXcel Therapeutics Eyenovia Lipocine (NASDAQ:LPCN) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the media prefer LPCN or APM? In the previous week, Lipocine had 1 more articles in the media than Aptorum Group. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.92 beat Lipocine's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptorum Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, LPCN or APM? Aptorum Group has lower revenue, but higher earnings than Lipocine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$500K65.06-$16.35M-$1.59-3.82Aptorum Group$430K17.50-$2.83MN/AN/A Do analysts recommend LPCN or APM? Lipocine presently has a consensus price target of $10.00, suggesting a potential upside of 64.47%. Given Lipocine's higher probable upside, equities research analysts clearly believe Lipocine is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more risk and volatility, LPCN or APM? Lipocine has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Does the MarketBeat Community favor LPCN or APM? Lipocine received 306 more outperform votes than Aptorum Group when rated by MarketBeat users. Likewise, 69.96% of users gave Lipocine an outperform vote while only 68.33% of users gave Aptorum Group an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34769.96% Underperform Votes14930.04% Aptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Is LPCN or APM more profitable? Aptorum Group's return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -38.58% -35.28% Aptorum Group N/A N/A N/A Do institutionals & insiders hold more shares of LPCN or APM? 9.1% of Lipocine shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 6.1% of Lipocine shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryLipocine beats Aptorum Group on 8 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.53M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / Sales17.50396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.495.324.665.02Net Income-$2.83M$153.56M$119.06M$225.46M7 Day Performance-11.94%0.13%0.80%0.37%1 Month Performance-19.94%15.23%5.65%3.57%1 Year Performance-9.75%41.14%36.75%29.43% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.9134 of 5 stars$1.45+1.4%N/A-13.0%$7.53M$430,000.000.0030LPCNLipocine1.5794 of 5 stars$5.54+2.2%$10.00+80.5%+137.5%$29.63M$4.80M-3.4810News CoverageITRMIterum Therapeutics2.8355 of 5 stars$1.29+6.6%$5.00+287.6%+67.1%$29.29MN/A-0.6510Gap UpESLAEstrella Immunopharma1.3098 of 5 stars$0.80-1.2%N/A-52.5%$29.10MN/A-0.41N/APositive NewsGap DownENLVEnlivex Therapeutics3.4122 of 5 stars$1.35-2.2%$6.00+344.4%+2.4%$28.90MN/A-1.1470News CoverageHigh Trading VolumeNAIINatural Alternatives International1.0223 of 5 stars$4.57-1.9%N/A-24.4%$28.89M$113.80M-3.72290Analyst ForecastINKTMiNK Therapeutics1.9469 of 5 stars$0.71-1.4%$9.00+1,160.5%-30.5%$28.23MN/A-1.4630News CoverageGap UpICCCImmuCell0.6704 of 5 stars$3.61-1.6%N/A-29.9%$28.20M$23.22M-6.8175Positive NewsPLURPluri0.7863 of 5 stars$5.01+4.2%N/A+14.4%$27.39M$326,000.00-0.85150Gap DownBTAIBioXcel Therapeutics4.1811 of 5 stars$0.67-7.0%$5.00+649.9%-85.4%$27.17M$2.40M-0.1990Short Interest ↑News CoverageEYENEyenovia2.9442 of 5 stars$0.49-7.5%$12.00+2,347.0%-63.9%$26.42M$31,405.00-0.6140 Related Companies and Tools Related Companies LPCN Competitors ITRM Competitors ESLA Competitors ENLV Competitors NAII Competitors INKT Competitors ICCC Competitors PLUR Competitors BTAI Competitors EYEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
